MA32563B1 - Dabigatran pour cathétérisme cardiaque de chirurgie percutanée - Google Patents

Dabigatran pour cathétérisme cardiaque de chirurgie percutanée

Info

Publication number
MA32563B1
MA32563B1 MA33616A MA33616A MA32563B1 MA 32563 B1 MA32563 B1 MA 32563B1 MA 33616 A MA33616 A MA 33616A MA 33616 A MA33616 A MA 33616A MA 32563 B1 MA32563 B1 MA 32563B1
Authority
MA
Morocco
Prior art keywords
dabigatran
percutaneous surgery
catheterism
cardiac
cardiac catheterism
Prior art date
Application number
MA33616A
Other languages
Arabic (ar)
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32563(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32563B1 publication Critical patent/MA32563B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne une nouvelle utilisation du dabigatran étéxilate de formule (i) éventuellement sous la forme de ses sels pharmaceutiquement acceptables ainsi que de nouvelles formulations médicamenteuses pouvant être utilisées à cette fin.
MA33616A 2008-08-19 2011-02-15 Dabigatran pour cathétérisme cardiaque de chirurgie percutanée MA32563B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19
PCT/EP2009/060592 WO2010020602A1 (fr) 2008-08-19 2009-08-17 Dabigatran pour cathétérisme cardiaque de chirurgie percutanée

Publications (1)

Publication Number Publication Date
MA32563B1 true MA32563B1 (fr) 2011-08-01

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33616A MA32563B1 (fr) 2008-08-19 2011-02-15 Dabigatran pour cathétérisme cardiaque de chirurgie percutanée

Country Status (19)

Country Link
US (1) US20110301201A1 (fr)
EP (1) EP2328580A1 (fr)
JP (1) JP2012500245A (fr)
KR (1) KR20110044230A (fr)
CN (1) CN102123707A (fr)
AR (1) AR073077A1 (fr)
AU (1) AU2009284217A1 (fr)
BR (1) BRPI0917507A2 (fr)
CA (1) CA2734794A1 (fr)
CL (1) CL2011000361A1 (fr)
CO (1) CO6290686A2 (fr)
EA (1) EA201100358A1 (fr)
EC (1) ECSP11010825A (fr)
IL (1) IL210005A0 (fr)
MA (1) MA32563B1 (fr)
MX (1) MX2011001612A (fr)
NZ (1) NZ591108A (fr)
TW (1) TW201022235A (fr)
WO (1) WO2010020602A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
ES2509117T3 (es) * 2010-03-01 2014-10-17 Ratiopharm Gmbh Composición farmacéutica oral que contiene dabigatran etexilato
EP2560966B1 (fr) 2010-03-30 2021-01-06 Verseon International Corporation Composés aromatiques multisubstitués utilisés comme inhibiteurs de la thrombine
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
CA2886094A1 (fr) * 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Procede de preparation d'etexilate de dabigatran ou d'un sel pharmaceutiquement acceptable de cette substance
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
EP2970141B1 (fr) 2013-03-15 2020-02-26 Verseon Corporation Halogénopyrazoles en tant qu'inhibiteurs de la thrombine
LT2968297T (lt) 2013-03-15 2019-01-10 Verseon Corporation Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
CA2960790A1 (fr) 2014-09-17 2016-03-24 Verseon Corporation Composes de pyridone substituee par pyrazolyl en tant qu'inhibiteurs de serine protease
EP3261639B1 (fr) 2015-02-27 2022-08-24 Verseon International Corporation Composés pyrazole substitués à utiliser en tant qu'inhibiteurs de sérine protéase
CA3106359A1 (fr) 2018-07-13 2020-01-16 Verseon International Corporation Inhibiteurs de la thrombine, formulations et utilisations associees

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210862B1 (pl) * 2002-03-07 2012-03-30 Boehringer Ingelheim Pharma Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji
EP1807086A1 (fr) * 2004-10-25 2007-07-18 Boehringer Ingelheim International GmbH Utilisation de dipyridamole en association avec des antithrombotiques pour traiter et prevenir des maladies thromboemboliques
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
CA2657270A1 (fr) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh Nouvelles indications pediatriques pour des inhibiteurs directs de la thrombine
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Also Published As

Publication number Publication date
BRPI0917507A2 (pt) 2015-11-17
CL2011000361A1 (es) 2011-06-17
AU2009284217A1 (en) 2010-02-25
EA201100358A1 (ru) 2011-10-31
EP2328580A1 (fr) 2011-06-08
US20110301201A1 (en) 2011-12-08
NZ591108A (en) 2012-11-30
AR073077A1 (es) 2010-10-13
CN102123707A (zh) 2011-07-13
MX2011001612A (es) 2011-03-04
IL210005A0 (en) 2011-02-28
JP2012500245A (ja) 2012-01-05
WO2010020602A1 (fr) 2010-02-25
TW201022235A (en) 2010-06-16
CO6290686A2 (es) 2011-06-20
CA2734794A1 (fr) 2010-02-25
ECSP11010825A (es) 2011-03-31
KR20110044230A (ko) 2011-04-28

Similar Documents

Publication Publication Date Title
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
MA29909B1 (fr) Derives de pyridazine
UA105911C2 (uk) Сульфонамідні похідні
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
MA38175A1 (fr) Lactames fusionnés à un aryle et hétéroaryle
PA8658301A1 (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA30781B1 (fr) Inhibiteur de kinase
MA33721B1 (fr) Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
UA107784C2 (en) Inhibitor of melanin production
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
MA34760B1 (fr) Composés et leurs utilisation
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA38679A1 (fr) Modulateurs du récepteur de cxcr7